Register Study of the Neoadjuvanten Treatment by Patients With Rectumcarcinoma

University Hospital Tuebingen78 enrolled

Overview

goal of this study is to check the effecivity, feasibility and toxicity of the chemoradiotherapy and hyperthermia

Radiation: 5x1,8Gy until 50,4 Gy Hyperthermia: 2x/week Chemotherapy: neoadjuvant= day 1-5 and day 29-33 5FU 1000mg/m2 adjuvant = 4 Cycles 5FU 500mg/m2 all 4 weeks

Study Type

OBSERVATIONAL

Enrollment

Conditions

Feasibilitystudy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: adenocarcinoma until 10 cm until ano UICC II+III 18-80 years old ECOG PS 0-2 Informed Consent Exclusion Criteria: cardiac insufficiency last 6 month heartattack nodal AV pressure III° hip prothesis cardiac pacemaker others contraindikations against the therapie radiation of pelvis chronic gestrointestinal desaese gestation or lactation previous radiotion pelvis previous Chemotherapie second carcinoma beside baslioma infiltation in analarea

Locations (1)

University Hospital Tuebingen

Tübingen, Baden-Wurttemberg, Germany

Outcomes

Primary Outcomes

remission

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.